# US 2024/0002846 A1 · Compositions and methods for the diagnosis and treatment of itch

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002846 A1
- Document ID: US20240002846A1
- Status: Published application
- Kind: A1
- Application number: 18/032,103
- Filed: 2021-10-15
- Published: 2024-01-04
- Earliest claimed: 2020-10-15
- Applicants: Duke University; Universidad Nacional Autónoma de México; Wake Forest University Health Sciences
- Inventors: Wolfgang Liedtke; Yong Chen; Tamara Rosenbaum; Tony Elvern Reeves
- Web page: https://patentgrep.com/patent/US20240002846A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12N 2310/141: MicroRNAs, miRNAs
- C12Q 2600/158: Expression markers
- C12Q 2600/178: miRNA, siRNA or ncRNA
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- G01N 2800/20: Dermatological disorders
- G01N 2800/205: Scaling palpular diseases, e.g. psoriasis, pytiriasis
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Disclosed herein are compositions and methods for treating a subject having an itch-related disorder, such as dermatological disorders or systemic disorders comprising itch. The methods may include determining the level of a biomarker in a biological sample from the subject. The biomarker may be selected from TRPV4 expression, lysophosphatidylcholine, and miRNA-146a expression, or a combination thereof. The subject may be identified as having the itch-related disorder when the level of the biomarker is greater in a sample from the subject than in a control. An anti-pruritic therapy may be administered to treat the subject having the itch-related disorder.

## Claims

### Claim 1

A method of treating a subject having an itch-related disorder, the method comprising:
determining the level of a biomarker in a biological sample from the subject, wherein the biomarker is selected from TRPV4 expression, lysophosphatidylcholine, and miRNA-146a expression, or a combination thereof; and
administering an anti-pruritic therapy to treat the subject identified as having the itch-related disorder, wherein the subject is identified as having the itch-related disorder when the level of the biomarker is greater in the biological sample than in a control sample.

### Claim 2

A method of treating an itch-related disorder in a subject, the method comprising:
(a) determining the level of a biomarker in a biological sample from the subject, wherein the biomarker is selected from TRPV4 expression, lysophosphatidylcholine, and miRNA-146a expression, or a combination thereof, and wherein the level of the biomarker is greater in the biological sample than in a control sample;
(b) diagnosing the subject as having an itch-related disorder based on the level of the biomarker determined in step (a); and
(c) administering an anti-pruritic therapy to the subject diagnosed as having an itch-related disorder in step (b).

### Claim 3

A method of diagnosing an itch-related disorder in a subject, the method comprising:
determining the level of a biomarker in a biological sample from the subject, wherein the biomarker is selected from TRPV4 expression, lysophosphatidylcholine, and miRNA-146a expression, or a combination thereof; and
diagnosing the subject as having an itch-related disorder when the level of the biomarker is greater in the biological sample than in a control sample.

### Claim 4 (depends on 3)

The method of claim 3, wherein the method further comprises administering an anti-pruritic therapy to the subject diagnosed as having an itch-related disorder.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the itch-related disorder comprises itch.

### Claim 6

A method of identifying an itch-related disorder in a subject, the method comprising:
(i) obtaining a biological sample from the subject;
(ii) identifying the presence of a biomarker in the subject, the biomarker selected from the group consisting of TRPV4, miRNA-146a, lysophosphatidylcholine, and combinations thereof;
(iii) quantifying the expression level of the biological sample, in which the presence of one or more of the biomarkers in an amount greater than the control is indicative of the itch-related disorder comprising itch; and
(iv) administering to the subject an appropriate anti-pruritic therapy if the level of biomarker is greater in the biological sample than in a control sample.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the biomarker is the level of TRPV4 expression.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the biomarker is the level of lysophosphatidylcholine.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the biomarker is the level of miRNA-146a expression.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the itch-related disorder is a dermatological disorder or a systemic disorder.

### Claim 11 (depends on 10)

The method of claim 10, wherein the itch-related disorder is a systemic disorder selected from liver disorder, kidney disorder, cancer, lymphoma, infection, or medication side-effect.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein the itch-related disorder is selected from the group consisting of cholestatic itch, uremic itch, pruritic psoriasis, and combinations thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein the level of TRPV4 expression or the level of miRNA-146a expression is an RNA expression level.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the level of the biomarker is determined by microarray analysis, or PCR, or a combination thereof.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the control sample is from a healthy subject.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the biological sample comprises skin.

### Claim 17 (depends on 16)

The method of claim 16, wherein the biological sample comprises skin keratinocytes.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the biological sample comprises blood.

### Claim 19 (depends on 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-2 and 4-18, wherein the anti-pruritic therapy is selected from the group consisting of moisturizers, capsaicin, salicylic acid, emollients, topical corticosteroids, topical calcineurin inhibitors, antihistamines, menthol, local anesthetics, cannabinoids, immunomodulators, antihistamines, antidepressants, μ-opiod receptor agonists, k-opiod receptor agonists, neuroleptics, substance P antagonist, immunosuppressants, methylnaltrexone, NGX-4010, TS-022, Serine proteases/PAR2 antagonists, IL-31 antibody, IL-4-receptor antibody, IL-13 antibody, TSLP-antibody, IL-5 antibody, and combinations thereof.

### Claim 20 (depends on 19)

The method of claim 19, wherein the anti-pruritic therapy comprises an immunomodulator.

### Claim 21 (depends on 20)

The method of claim 20, wherein the immunomodulator comprises a TRPV4 inhibitor.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the subject is a mammal.

### Claim 23 (depends on 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-2 and 4-22, wherein the anti-pruritic therapy comprises a TRPV4 inhibitor.

### Claim 24 (depends on 23)

The method of claim 23, wherein the TRPV4 inhibitor binds to a C-terminal region of TRPV4.

### Claim 25 (depends on 24)

The method of claim 24, wherein the TRPV4 inhibitor binds at least one amino acid in a motif comprising K750-W772 of Xenopus TRPV4 or K754-W776 of mammalian TRPV4 or an amino acid corresponding thereto.

### Claim 26 (depends on 24)

The method of claim 24, wherein the TRPV4 inhibitor binds at least one amino acid in a motif comprising R742-W772 of Xenopus TRPV4 or R746-W776 of mammalian TRPV4 or an amino acid corresponding thereto.

### Claim 27 (depends on 24)

The method of claim 24, wherein the TRPV4 inhibitor binds at least one amino acid in a motif comprising K750-W772 and R742 of Xenopus TRPV4 or K754-W776 and R746 of mammalian TRPV4 or an amino acid corresponding thereto.

### Claim 28 (depends on 24)

The method of claim 24, wherein the TRPV4 inhibitor binds Arg-746 of mammalian TRPV4 or Arg-742 of Xenopus TRPV4 or an amino acid corresponding thereto.

### Claim 29 (depends on 24)

The method of claim 24, wherein the TRPV4 inhibitor binds at least one amino acid selected from K754, R757, R774, and W776 of mammalian TRPV4 or an amino acid corresponding thereto.

### Claim 30

A method of screening for a compound that modulates TRPV4, the method comprising:
testing a plurality of compounds for binding to wild-type TRPV4 to determine from the plurality of compounds a subset of compounds that bind wild-type TRPV4; and
testing the subset of compounds that bind wild-type TRPV4 for binding to at least one mutant TRPV4, wherein the mutant TRPV4 comprises a mutation of at least one amino acid in the motif corresponding to K746-W776 of mammalian TRPV4, or an amino acid corresponding thereto, to determine from the subset of compounds a compound that binds wild-type TRPV4 but not the mutant TRPV4.

### Claim 31 (depends on 30)

The method of claim 30, wherein at least one amino acid in the motif corresponding to K754-W776 of mammalian TRPV4 is mutated to an alanine.

### Claim 32 (depends on 30)

The method of claim 30, wherein at least one amino acid in the motif corresponding to K754-W776 of mammalian TRPV4 is mutated to a glycine.

### Claim 33 (depends on 30)

The method of claim 30, wherein at least one amino acid selected from K754, R757, R774, and W776 of mammalian TRPV4, or an amino acid corresponding thereto, is mutated.

### Claim 34 (depends on 30, 31, 32, 33)

The method of any one of claims 30-33, wherein the mutant TRPV4 has activity as an ion channel.

### Claim 35 (depends on 30, 31, 32, 33, 34)

The method of any one of claims 30-34, further comprising determining the effect of the compound that binds wild-type TRPV4 but not the mutant TRPV4 on the activity of wild-type TRPV4.

### Claim 36 (depends on 30, 31, 32, 33, 34, 35)

The method of any one of claims 30-35, wherein the compound that binds wild-type TRPV4 but not the mutant TRPV4 inhibits the activity of wild-type TRPV4.

### Claim 37 (depends on 30, 31, 32, 33, 34, 35)

The method of any one of claims 30-35, wherein the compound that binds wild-type TRPV4 but not the mutant TRPV4 increases the activity of wild-type TRPV4.

### Claim 38 (depends on 30, 31, 32, 33, 34, 35)

The method of any one of claims 30-35, wherein the compound that binds wild-type TRPV4 but not the mutant TRPV4 inhibits or reduces the binding of LCP to wild-type TRPV4.
